New hope for advanced cancer: experimental drug DM005 enters first human trials
NCT ID NCT06515990
First seen Jan 19, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This early-phase trial tests an experimental drug, DM005, in about 136 people with advanced solid tumors (like lung, head and neck, or other cancers) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how well it works. Participants receive DM005 as an intravenous infusion every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, New South Wales, Australia
Contact
-
Henry Ford Cancer Institute
RECRUITINGDetroit, Michigan, 48202, United States
Contact
-
ICON Cancer Center
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact
-
Macquarie University Hospital
RECRUITINGNorth Ryde, New South Wales, Australia
Contact
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Sarah Cannon Research Institute at Mary Crowley
RECRUITINGDallas, Texas, 75251, United States
Contact
Conditions
Explore the condition pages connected to this study.